The ANS1 test provides clinicians with the technology that can help detect and possibly prevent the onset of early disease. ANS1 software also has data management features that are cleared for use with a number of FDA-approved devices.
The ANS1 is approved for use by the FDA in addition to: the American Heart Association, the American Heart and Lung Association, the American Diabetes Association, the American Academy of Family Physicians, and the American Academy of Neurology.
As a medical device that tests the functioning of your autonomous nervous system, the ANS1 provides a simple way that doctors can test for a host of possible issues. Three sensors are placed on the patient’s feet, arms, and fingers in order to achieve a quick gauge of the patient’s blood pressure, heart rate, and other vital signs that could be clinically significant for early disease detection given certain other warning signs.
The ANS1 test is ideally performed when the patient is in a relaxed, resting state. Patients, though, will be asked to stand during part of the test and perform rhythmic breathing exercises so that the clinician on site can gauge the effects of standing and breathing on blood pressure and heart rate. The ANS1 is cleared by the FDA as extremely safe to use on patients, and the use of ANS1 is supported by over a decade of clinical research.
The ANS1 seeks to detect early disease onset through analyzing the functioning of the autonomous nervous system. The autonomous nervous system is responsible for controlling involuntary functions like breathing and heart rate. Involuntary functions like control of blood pressure and digestion are also undertaken by the autonomous nervous system.
Partial failure of the autonomous nervous system can impact the functioning of the gastrointestinal system and cardiac system, so it’s extremely important that clinicians have early indications of possible malfunctioning of the autonomic nervous system through a test like the ANS1. The ANS1 is cleared by the FDA to detect everything from heart disease to diabetes because the autonomous nervous system controls so many of the body’s involuntary functions.
The exam itself is non-invasive and only takes up 7 minutes of the patient’s time. Fortunately, the exam is not at all painful for most patients and there have been no reported side effects from the ANS1 test of the autonomous nervous system. Clinicians may find that their diagnostic information becomes that much richer when they upload results from the ANS1 with other examinations.
For instance, results from an ANS1 could be combined with results from other FDA-cleared devices like a galvanic skin response device as well as an oximeter or blood pressuring reading device. An oximeter is a device that clinicians use for measuring the amount of oxygenated hemoglobin in the patient’s blood. Low levels could be related to anemia.
Fortunately for clinicians, the ANS1 has data management capabilities that make it a logical partner with other medical devices.
Combining the results on a possibly anemic patient obtained from an oximeter with the rich clinical information gleaned from the ANS1 test could create synergistic effects for clinicians that allow them to discover more information about a particular patient’s risk factors.
In fact, autonomous nervous system testing is recommended by the American Diabetic Association before any patient is diagnosed with Type 2 diabetes. The American Diabetes Association recommends that patients with Type 1 diabetes have their autonomous nervous system functioning tested at least every five years with a test like the ANS1.
The ANS1 test can also help detect endothelial function, risk of cardiac autonomic neuropathy, and provide a means of assessing heart-rate variability.